[go: up one dir, main page]

HK1248567A1 - Compositions and methods of treating acute myeloid leukemia - Google Patents

Compositions and methods of treating acute myeloid leukemia Download PDF

Info

Publication number
HK1248567A1
HK1248567A1 HK18108369.6A HK18108369A HK1248567A1 HK 1248567 A1 HK1248567 A1 HK 1248567A1 HK 18108369 A HK18108369 A HK 18108369A HK 1248567 A1 HK1248567 A1 HK 1248567A1
Authority
HK
Hong Kong
Prior art keywords
methods
myeloid leukemia
compositions
acute myeloid
treating acute
Prior art date
Application number
HK18108369.6A
Other languages
Chinese (zh)
Inventor
David Avigan
Jacalyn ROSENBLATT
Donald Kufe
Original Assignee
Dana Farber Cancer Institute, Inc.
Beth Israel Deaconess Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center filed Critical Dana Farber Cancer Institute, Inc.
Publication of HK1248567A1 publication Critical patent/HK1248567A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides compositions and methods for treating acute myeloid leukemia.
HK18108369.6A 2015-03-30 2016-03-30 Compositions and methods of treating acute myeloid leukemia HK1248567A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562140325P 2015-03-30 2015-03-30
US62/140,325 2015-03-30
US201562257943P 2015-11-20 2015-11-20
US62/257,943 2015-11-20
PCT/US2016/024980 WO2016160968A1 (en) 2015-03-30 2016-03-30 Compositions and methods of treating acute myeloid leukemia

Publications (1)

Publication Number Publication Date
HK1248567A1 true HK1248567A1 (en) 2018-10-19

Family

ID=55808849

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18108369.6A HK1248567A1 (en) 2015-03-30 2016-03-30 Compositions and methods of treating acute myeloid leukemia

Country Status (5)

Country Link
EP (1) EP3277291A1 (en)
AU (1) AU2016243194A1 (en)
CA (1) CA2977753A1 (en)
HK (1) HK1248567A1 (en)
WO (1) WO2016160968A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108368170B (en) 2015-07-13 2022-04-15 西托姆克斯治疗公司 Anti-PD-1 antibody, activatable anti-PD-1 antibody and method of use
US20190343939A1 (en) * 2017-01-11 2019-11-14 Dana-Farber Cancer Institute, Inc. Personalized vaccines
CN111088360A (en) * 2020-01-17 2020-05-01 暨南大学 Application of PD1-CTLA4 and/or PDL2-CTLA4 in the preparation of AML prognosis prediction kit

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434486T2 (en) 1993-06-24 2006-07-06 Advec Inc. ADENOVIRUS VECTORS FOR GENE THERAPY
ATE437232T1 (en) 1993-10-25 2009-08-15 Canji Inc RECOMBINANT ADENOVIRUS VECTOR AND METHOD OF USE
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US6653848B2 (en) 2000-09-18 2003-11-25 Agilent Technologies, Inc. Method and apparatus for linear characterization of multi-terminal single-ended or balanced devices
CA2704232C (en) * 2007-11-08 2017-05-02 Dana-Farber Cancer Institute, Inc. Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28

Also Published As

Publication number Publication date
WO2016160968A1 (en) 2016-10-06
CA2977753A1 (en) 2016-10-06
AU2016243194A1 (en) 2017-09-21
EP3277291A1 (en) 2018-02-07

Similar Documents

Publication Publication Date Title
ZA202107931B (en) Anti-tau antibodies and methods of use
MX2020006812A (en) Irak degraders and uses thereof.
MX2021000710A (en) Compositions comprising bacterial strains.
MX2019003623A (en) Compositions and methods for treating ophthalmic conditions.
MX2020005213A (en) Mk2 inhibitors and uses thereof.
HK1258098A1 (en) Methods of treating cancer
MX2018006632A (en) Bicyclic inhibitors of pad4.
MX2018009325A (en) Compounds and methods of treating rna-mediated diseases.
MX2019001471A (en) Anti-siglec-7 antibodies for the treatment of cancer.
MX2018004674A (en) Modulators of sestrin-gator2 interaction and uses thereof.
MX2018006700A (en) Aza-benzimidazole inhibitors of pad4.
WO2015120062A3 (en) Therapeutic compounds and compositions
EP3137085A4 (en) Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds
IL322584A (en) Compositions comprising methylphenidate-prodrugs, processes of making and using the same
MX2018000715A (en) Methods for treating cancer using apilimod.
PH12017501864A1 (en) Compositions and methods for treating autism
EP4218736A3 (en) Compositions comprising 15-hepe
HK1255835A1 (en) Therapeutic compositions and methods for treating hepatitis b
IL261160B (en) Methods of treating acute myeloid leukemia
HK1255221A1 (en) Methods of treatment using cadotril compositions
HK1250145A1 (en) Compositions and methods of treating multiple myeloma
HK1248567A1 (en) Compositions and methods of treating acute myeloid leukemia
EP3535025A4 (en) Compositions and methods for treating patients suffering from glioma or leukemia
EP3397257A4 (en) Compositions and nethods for treating brain dysfunction
HK40091518A (en) Composition for the treatment of veisalgia